Exhaled Biomarkers in Idiopathic Pulmonary Fibrosis—A Six-Month Follow-Up Study in Patients Treated with Pirfenidone

Exhaled Biomarkers in Idiopathic Pulmonary Fibrosis—A Six-Month Follow-Up Study in Patients Treated with Pirfenidone

The mechanism of action of pirfenidone in idiopathic pulmonary fibrosis (IPF) has not been fully elucidated. To offer additional insight, we evaluated the change in the cytokine profile in exhaled breath condensate (EBC) following a six-month treatment with pirfenidone in patients with IPF. EBC conc...

Full description

Bibliographic Details
Main Authors: Kaja Jaskiewicz, Katarzyna Mycroft, Marta Maskey-Warzechowska, Karolina Paralusz, Natalia Siemiez, Patrycja Nejman-Gryz, Malgorzata Barnas, Rafal Krenke, Katarzyna Gorska
Format: Article
Language:English
Published: MDPI AG 2020-08-01
Series:Journal of Clinical Medicine
Subjects:
antifibrotic treatment
exhaled breath condensate
pulmonary fibrosis
interleukin
vascular endothelial growth factor
Online Access:https://www.mdpi.com/2077-0383/9/8/2523

Internet

https://www.mdpi.com/2077-0383/9/8/2523

Similar Items